Cover Image
Market Research Report

Epstein-Barr Virus (HHV-4) Infections - Pipeline Review, H2 2018

Published by Global Markets Direct Product code 484631
Published Content info 209 Pages
Delivery time: 1-2 business days
Price
Back to Top
Epstein-Barr Virus (HHV-4) Infections - Pipeline Review, H2 2018
Published: September 26, 2018 Content info: 209 Pages
Description

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Epstein-Barr Virus (HHV-4) Infections - Pipeline Review, H2 2018, provides an overview of the Epstein-Barr Virus (HHV-4) Infections (Infectious Disease) pipeline landscape.

Epstein-Barr virus (EBV) or human herpes virus 4 virus is a member of the Herpesviridae family. It is one of the most common human viruses to cause cancer in humans and is associated with a wide range of human cancers originating from epithelial cells, lymphocytes and mesenchymal cells. It spreads most commonly through bodily fluids. It can also spread through blood and semen during sexual contact, blood transfusions, and organ transplantations. Symptoms of EBV infections include fatigue, fever, and inflamed throat, swollen lymph nodes in the neck, enlarged spleen, swollen liver and rash. Treatment includes over-the-counter pain and fever medications to get relief from the symptoms of the disease.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Epstein-Barr Virus (HHV-4) Infections - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Epstein-Barr Virus (HHV-4) Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Epstein-Barr Virus (HHV-4) Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Epstein-Barr Virus (HHV-4) Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 8, 4, 9 and 7 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Preclinical and Discovery stages comprises 1, 9, 2, 5 and 4 molecules, respectively.

Epstein-Barr Virus (HHV-4) Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Epstein-Barr Virus (HHV-4) Infections (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Epstein-Barr Virus (HHV-4) Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Epstein-Barr Virus (HHV-4) Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Epstein-Barr Virus (HHV-4) Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Epstein-Barr Virus (HHV-4) Infections (Infectious Disease)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Epstein-Barr Virus (HHV-4) Infections (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Epstein-Barr Virus (HHV-4) Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Product Code: GMDHC10790IDB

Table of Contents

  • Table of Contents
  • Introduction
  • Epstein-Barr Virus (HHV-4) Infections - Overview
  • Epstein-Barr Virus (HHV-4) Infections - Therapeutics Development
  • Epstein-Barr Virus (HHV-4) Infections - Therapeutics Assessment
  • Epstein-Barr Virus (HHV-4) Infections - Companies Involved in Therapeutics Development
  • Epstein-Barr Virus (HHV-4) Infections - Drug Profiles
  • Epstein-Barr Virus (HHV-4) Infections - Dormant Projects
  • Epstein-Barr Virus (HHV-4) Infections - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Epstein-Barr Virus (HHV-4) Infections, H2 2018
  • Number of Products under Development by Companies, H2 2018
  • Number of Products under Development by Companies, H2 2018 (Contd..1), H2 2018
  • Number of Products under Development by Universities/Institutes, H2 2018
  • Number of Products under Development by Universities/Institutes, H2 2018 (Contd..1), H2 2018
  • Products under Development by Companies, H2 2018
  • Products under Development by Companies, H2 2018 (Contd..1), H2 2018
  • Products under Development by Universities/Institutes, H2 2018
  • Products under Development by Universities/Institutes, H2 2018 (Contd..1), H2 2018
  • Number of Products by Stage and Target, H2 2018
  • Number of Products by Stage and Mechanism of Action, H2 2018
  • Number of Products by Stage and Route of Administration, H2 2018
  • Number of Products by Stage and Molecule Type, H2 2018
  • Epstein-Barr Virus (HHV-4) Infections - Pipeline by Advenchen Laboratories LLC, H2 2018
  • Epstein-Barr Virus (HHV-4) Infections - Pipeline by Atara Biotherapeutics Inc, H2 2018
  • Epstein-Barr Virus (HHV-4) Infections - Pipeline by Biotron Ltd, H2 2018
  • Epstein-Barr Virus (HHV-4) Infections - Pipeline by bluebird bio Inc, H2 2018
  • Epstein-Barr Virus (HHV-4) Infections - Pipeline by Bristol-Myers Squibb Co, H2 2018
  • Epstein-Barr Virus (HHV-4) Infections - Pipeline by Cell Medica Ltd, H2 2018
  • Epstein-Barr Virus (HHV-4) Infections - Pipeline by Genocea Biosciences Inc, H2 2018
  • Epstein-Barr Virus (HHV-4) Infections - Pipeline by Omeros Corp, H2 2018
  • Epstein-Barr Virus (HHV-4) Infections - Pipeline by Ono Pharmaceutical Co Ltd, H2 2018
  • Epstein-Barr Virus (HHV-4) Infections - Pipeline by Oxford Vacmedix UK Ltd, H2 2018
  • Epstein-Barr Virus (HHV-4) Infections - Pipeline by TC BioPharm Ltd, H2 2018
  • Epstein-Barr Virus (HHV-4) Infections - Pipeline by Tessa Therapeutics Pte Ltd, H2 2018
  • Epstein-Barr Virus (HHV-4) Infections - Pipeline by Vectorite Biomedical Inc, H2 2018
  • Epstein-Barr Virus (HHV-4) Infections - Pipeline by Viracta Therapeutics Inc, H2 2018
  • Epstein-Barr Virus (HHV-4) Infections - Pipeline by Vironika LLC, H2 2018
  • Epstein-Barr Virus (HHV-4) Infections - Pipeline by ViroStatics srl, H2 2018
  • Epstein-Barr Virus (HHV-4) Infections - Dormant Projects, H2 2018
  • Epstein-Barr Virus (HHV-4) Infections - Dormant Projects, H2 2018 (Contd..1), H2 2018

List of Figures

  • Number of Products under Development for Epstein-Barr Virus (HHV-4) Infections, H2 2018
  • Number of Products under Development by Companies, H2 2018
  • Number of Products under Development by Universities/Institutes, H2 2018
  • Number of Products by Top 10 Targets, H2 2018
  • Number of Products by Stage and Top 10 Targets, H2 2018
  • Number of Products by Top 10 Mechanism of Actions, H2 2018
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018
  • Number of Products by Routes of Administration, H2 2018
  • Number of Products by Stage and Routes of Administration, H2 2018
  • Number of Products by Molecule Types, H2 2018
  • Number of Products by Stage and Molecule Types, H2 2018
Back to Top